Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

CARMIEL, Israel, May 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx^® plant cell–based protein expression system, today announced that it will participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference, taking place on Tuesday, May 20, 2025 at the Nasdaq headquarters in New York City, New York.

Eyal Rubin, the Company's Sr. Vice President and Chief Financial Officer, will deliver a company presentation and be available for one-on-one investor meetings throughout the event.

Investors interested in scheduling a meeting with the Company's management team should contact their H.C. Wainwright representative or email [email protected].

Event Details

Conference:   3rd Annual H.C. Wainwright BioConnect Investor Conference

Date:               Tuesday, May 20, 2025

Location:        Nasdaq World Headquarters in New York City (151 W. 43rd Street)

Webcast Details

A webcast of the live presentation will be available at 4:30 pm, Eastern Daylight Time (EDT), via the following links:

Company Link:         https://ir.protalix.com/news-events/events

Webcast Link:           https://journey.ct.events/view/c15f7813-e688-4a3e-911e-358a9c0562b8

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio^®, was approved by both the FDA and the European Medicines Agency in May 2023.

Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others.

Investor Contact: 
Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
[email protected] 

Logo: https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg

SOURCE Protalix BioTherapeutics, Inc.